• Of these, patients who received 24 373 administrations of chemotherapy with a low emetic risk (47.8%) and 633 administrations of chemotherapy with a minimal emetic risk (2.8%) were prescribed serotonin receptor antagonists and dexamethasone. (urotoday.com)
  • EMEND is the first in a new class of antiemetic treatments called neurokinin 1 (NK1) receptor antagonists that treat chemotherapy-induced nausea and vomiting. (hospitalhealthcare.com)
  • e.g., palonosetron) and neurokinin-1 receptor antagonists (NK1RAs). (biomedcentral.com)
  • Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists. (uchicago.edu)
  • Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. (uchicago.edu)
  • Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. (uchicago.edu)
  • Check out the study "Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant" to delve into the key findings and implications. (crs-group.de)
  • This manuscript reviews the mechanisms presumed to underly RCC/UCC together with the rationale and clinical evidence for several targeted therapies currently under clinical investigation, including transient receptor potential channel antagonists, P2X3-receptor antagonists, voltage-gated sodium channel blockers, neuromodulators, and neurokinin-1-receptor antagonists. (qub.ac.uk)
  • This explains the failure of substance P/neurokinin-1 receptor antagonists and the success of blocking CGRP mechanisms for relieving the pain of acute migraine. (medlink.com)
  • Neurokinin A (NKA), formerly known as Substance K, is a neurologically active peptide translated from the pre-protachykinin gene. (wikipedia.org)
  • Neurokinin A (formally known as substance K) is a member of the tachykinin family of neuropeptide neurotransmitters. (wikipedia.org)
  • It is produced from the same preprotachykinin A gene as the neuropeptide substance P. Both substance P and neurokinin A are encoded by the same mRNA, which when alternatively spliced can be translated into either compound. (wikipedia.org)
  • 2008 Sep;295(3):C679-91 Like Substance P [SP], Neurokinin A is present in excitatory neurons and secretory cells of the hypothalamic-pituitary-adrenal axis. (wikipedia.org)
  • EMEND ® is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. (nih.gov)
  • A subset of these receptors plays an important role in pain, including the neurokinin-1 (NK1) receptor, which is activated by a pain-transmitting neuropeptide called substance P. (sciencemission.com)
  • and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. (yahoo.com)
  • An azido derivative of [3H2](2S, 3S)-cis-2-(diphenylmethyl)-N-((2-methoxyphenyl) methyl)-1-azabicyclo[2.2.2]octon-3-amine (CP-96,345), a potent nonpeptide antagonist of the substance P (SP) (neurokinin-1) receptor, was synthesized and shown to have an affinity for the human SP receptor similar to that of the parent compound, CP-96,345. (shengsci.com)
  • This is a receptor for the tachykinin neuropeptide substance K (neurokinin A). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. (idrblab.net)
  • Fosnetupitant and palonosetron work by blocking natural substances in the body (such as substance P/neurokinin 1, serotonin) that cause vomiting. (clarksnutrition.com)
  • It works by blocking the action of neurokinin and substance P, natural substances in the brain that cause nausea and vomiting. (medlineplus.gov)
  • Recent studies in patients have identified the presence of neurochemicals, such as Substance P, in forelimb tendons in association with chronic tennis elbow. (cdc.gov)
  • Spinal cords were collected, frozen sectioned and examined immunohistochemically for Substance P, Neurokinin 1, and NMDAr1. (cdc.gov)
  • Aprepitant acts as an inhibitor of the binding of substance P to the neurokinin-1 receptor and, consequently, may reduce the frequency of paclitaxel-induced HSR. (elsevierpure.com)
  • Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. (uchicago.edu)
  • The neurokinin-1 (NK1) antagonist aprepitant represents a new class of antiemetic currently in clinical development. (brad.ac.uk)
  • Using data obtained in 2 Phase II clinical trials of aprepitant in patients receiving chemotherapy based on the highly emetogenic chemotherapeutic agent cisplatin, we compared the time course of antiemetic effect of aprepitant, a 5-HT3 antagonist, or a combination of both. (brad.ac.uk)
  • While aprepitant has a prophylactic effect against vomiting caused by high-dose cisplatin, the benefits of aprepitant have not been clearly demonstrated in patients receiving paclitaxel and carboplatin (TC) combination chemotherapy. (elsevierpure.com)
  • Patients received aprepitant or placebo together with both a 5-HT 3 receptor antagonist and dexamethasone prior to chemotherapy. (elsevierpure.com)
  • P = 0.014), and patients showing complete response (61.6 vs. 47.3 %, P = 0.0073) was significantly higher in the aprepitant group than in the placebo group. (elsevierpure.com)
  • Conclusion: The administration of aprepitant did not have a prophylactic effect on the HSR but was effective in reducing nausea and vomiting in gynecologic cancer patients receiving TC combination chemotherapy. (elsevierpure.com)
  • Patients with a malignant solid tumor who would receive HEC containing 50 mg/m 2 or more cisplatin were randomly assigned to either palonosetron (0.75 mg) arm (Arm P) or granisetron (1 mg) arm (Arm G), on day 1, both arms with dexamethasone (12 mg on day 1 and 8 mg on days 2-4) and aprepitant (125 mg on day 1 and 80 mg on days 2-3). (medscape.com)
  • Aprepitant, a neurokinin-1 (NK-1) receptor antagonist, and palonosetron, a second-generation 5-HT 3 RA, are two recently introduced antiemetic agents expected to improve control of CINV. (medscape.com)
  • [ 3 , 4 ] Current antiemesis guidelines from multiple organizations [American Society of Clinical Oncology (ASCO), Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology (MASCC/ESMO), and National Comprehensive Cancer Network (NCCN)] recommend aprepitant-containing triplet regimens as the standard antiemetic prophylaxis for patients receiving HEC. (medscape.com)
  • Although we focused on the neurokinin-1 receptor, our findings are likely applicable to many G-protein coupled receptors because many of them show sustained signaling within cells, and therefore require drugs that can enter cells and block the receptors in endosomes," said the senior author. (sciencemission.com)
  • The new drug compound called MLE4901, tested on women who suffered severe flushing, works by targeting receptors in the brain, blocking a chemical called neurokinin B (NKB). (telegraph.co.uk)
  • The use of antiemetic drugs for patients receiving chemotherapy with low or minimal emetic risk has been recognized as a growing concern for health care costs and patients' welfare. (urotoday.com)
  • To describe the pattern in Japan of overprescribing prophylactic antiemetic drugs to patients who have received intravenous chemotherapy with minimal or low emetic risk. (urotoday.com)
  • The percentage of chemotherapy administration involving patients prescribed prophylactic antiemetic drugs, namely, a neurokinin 1 receptor antagonist, serotonin receptor antagonist, and/or dexamethasone, was calculated. (urotoday.com)
  • A substantial number of patients receiving chemotherapy with minimal and low emetic risk were prescribed potentially unnecessary prophylactic antiemetic drugs. (urotoday.com)
  • Despite significant progress in its management, nausea and vomiting continues to affect around eight in 10 cancer patients receiving chemotherapy and remains one of the most feared side-effects of the treatment. (hospitalhealthcare.com)
  • Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled. (biomedcentral.com)
  • We recommend a 3-antiemetic combination prophylaxis for CRC patients treated with L-OHP-based chemotherapy, especially for female patients. (biomedcentral.com)
  • Whereas chemotherapy-induced nausea and vomiting (CINV) were less prevalent for CRC patients on fluorouracil-based chemotherapy, they are a common adverse event for patients treated with L-OHP. (biomedcentral.com)
  • CINV impairs patients' quality of life and often causes delay or refusal of curative chemotherapy among such patients [ 7 ]. (biomedcentral.com)
  • Especially, patients who receive receiving either high (HEC) or moderate (MEC) emetogenic chemotherapy have a high incidence of CINV. (biomedcentral.com)
  • Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. (uchicago.edu)
  • Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. (uchicago.edu)
  • HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. (uchicago.edu)
  • Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). (uchicago.edu)
  • Patients indicate that among the most feared side effects of cancer are chemotherapy-induced nausea and vomiting (CINV), with up to 80% of patients affected if appropriate prophylaxis is not administered. (emjreviews.com)
  • CINV affects patient quality of life, may interfere with chemotherapy compliance which can possibly influence cancer survival outcomes, and results in greater healthcare resource utilisation. (emjreviews.com)
  • The use of netupitant with palonosetron (NEPA), a fixed combination therapy administered orally once per chemotherapy cycle, as well as mobile health (mHealth) apps may help with guideline adherence and patient compliance. (emjreviews.com)
  • Furthermore, the majority of treatment failures in patients who received the NK1 antagonist occurred within the first 8¿12 h of chemotherapy, whereas the treatment failures in patients who received a 5-HT3 antagonist were more evenly distributed over time. (brad.ac.uk)
  • Methods: Data were pooled for 140 patients from three multicenter, prospective, single-arm, open-label phase II studies evaluating the efficacy and safety of olanzapine for managing nausea and vomiting induced by carboplatin-based chemotherapy. (elsevierpure.com)
  • Conclusions: The findings suggest that antiemetic regimens containing low-dose (5 mg) olanzapine could be effective and safe for patients receiving carboplatin-based chemotherapy. (elsevierpure.com)
  • Methods: We conducted a multicenter, placebo-controlled, double-blind, randomized study in Japanese patients with gynecologic cancer who received TC combination chemotherapy. (elsevierpure.com)
  • Chemotherapy-induced nausea and vomiting (CINV) is a non-hematologic toxicity of chemotherapy that severely impairs the quality of life of patients and reduces their treatment compliance. (medscape.com)
  • [ 8 ] In patients receiving moderately emetogenic chemotherapy (MEC), better CINV control was obtained with palonosetron than with a first-generation 5-HT 3 RA, [ 9 ] which supports current guideline recommendations for palonosetron use as a part of antiemetic premedication for MEC. (medscape.com)
  • Astellas reports positive topline results from pivotal trials of a neurokinin-3 receptor antagonist for post-menopausal vasomotor symptoms . (medpagetoday.com)
  • The neurokinin 1 receptor (NK1R) antagonist serlopitant was the only intervention that we could assess. (cochrane.org)
  • Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients: A Randomized Clinical Trial. (stanford.edu)
  • We pooled data from two prospective observational studies in Japan and one phase III clinical trial to assess whether delayed CINV could be controlled with a combination of three antiemetics adding a neurokinin-1 receptor antagonist and identified individual risk factors, using an inverse probability treatment-weighted analysis. (biomedcentral.com)
  • Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. (uchicago.edu)
  • Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. (uchicago.edu)
  • Over the entire observation period (up to 7 days post-cisplatin), patients who received the NK1 antagonist had a superior prevention of emesis. (brad.ac.uk)
  • However, in the first 24 h after cisplatin, emesis occurred in fewer patients who received the 5-HT3 antagonist than in patients who did not receive this class of drug. (brad.ac.uk)
  • Surprisingly, there was no significant difference in CINV control between the patients treated with or without neurokinin-1 receptor antagonist. (elsevierpure.com)
  • It is astounding that doctors who administer intravenous magnesium to save the lives of patients who are suffering a severe asthma attack do not recommend that their patients consume at least the recommended daily allowance (the amount necessary to prevent deficiency symptoms like asthma and heart disease) of magnesium each day. (electroherbalism.com)
  • Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. (uchicago.edu)
  • Intravenous administration of CGRP to patients prone to migraine can induce migraine-like headache. (medlink.com)
  • A randomized clinical trial of intravenous methylprednisolone with two protocols in patients with Graves' Orbitopathy. (medscape.com)
  • high-flow oxygen, n=5), and seven patients received intravenous corticosteroids. (accjournal.org)
  • Methods: We prospectively collected the clinical information of patients with sICAS who underwent percutaneous angioplasty and/or stenting (PTAS) or aggressive medical therapy from March 2020 to February 2022. (bvsalud.org)
  • DUBLIN - Can an investigational drug best known for reducing itch in dermatitis patients really lower the risk of COVID-19 patients progressing to acute respiratory distress syndrome (ARDS)? (bioworld.com)
  • Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. (uchicago.edu)
  • In another prospective study, all 16 patients admitted to the ICU for acute hypercapnic respiratory failure had sleep apnea when polysomnography (PSG) was conducted after their ICU discharge [ 7 ]. (accjournal.org)
  • CONCLUSIONS: Our results did not support thrombectomy-alone administration within 3-4.5 h in patients with acute ischemic stroke from large-vessel occlusion in the subgroup analysis of DIRECT-MT. (bvsalud.org)
  • By definition, either anosmia (lack of sense of smell) or severe hyposmia is present in patients with Kallmann syndrome, in contrast to patients with idiopathic hypogonadotropic hypogonadism, whose sense of smell is normal. (medscape.com)
  • MRI of the brain in patients with Kallmann syndrome (KS) and idiopathic hypogonadotropic hypogonadism (IHH). (medscape.com)
  • Deficient hypothalamic GnRH secretion underlies the markedly abnormal gonadotropin secretion patterns in most patients with Kallmann syndrome or idiopathic hypogonadotropic hypogonadism. (medscape.com)
  • [ 3 ] In addition, mutations of the gene encoding chromodomain-helicase DNA-binding protein 7 ( CHD7 ) have been found in some patients with Kallmann syndrome or idiopathic hypogonadotropic hypogonadism, some of whom have features of the CHARGE syndrome (characterized by delayed growth and development, congenital cardiac defects, dysmorphic ears, hearing loss, coloboma of the eyes). (medscape.com)
  • 2009). "TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. (chuv.ch)
  • [ 3 ] In addition, mutations of the gene encoding chromodomain-helicase DNA-binding protein 7 ( CHD7 ) have been found in some patients with Kallmann syndrome or idiopathic hypogonadotropic hypogonadism. (medscape.com)
  • This patient presented with hypogonadotropic hypogonadism, despite high levels of immunoreactive serum LH. (medscape.com)
  • In another patient, a mutation in the prohormone convertase gene (PC1) led to hypogonadotropic hypogonadism, in addition to extreme obesity, hypocortisolemia, and deficient conversion of proinsulin to insulin. (medscape.com)
  • Studies have shown that stress-induced activation of the noradrenergic prefrontal lobe system may be under the control of both endogenously released corticotrophin-releasing hormone and SP and neurokinin A. This study directly links the secretion of neurokinin A and SP to certain forms of depression characterized by the corticoid receptor hypothesis of depression. (wikipedia.org)
  • A second patient had a different homozygous mutation in the LH beta subunit gene that prevented LH heterodimerization and secretion. (medscape.com)
  • Modified from: Sun J, Ramnath RD, Tamizhselvi R, Bhatia M."Neurokinin A engages neurokinin-1 receptor to induce NF-kappaB-dependent gene expression in murine macrophages: implications of ERK1/2 and PI 3-kinase/Akt pathways. (wikipedia.org)
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. (yahoo.com)
  • However, some drugs have a better side-effect profile than others, enabling doctors to adjust treatment regimens to the advantage of patients in certain situations. (wikidoc.org)
  • These include better adherence by healthcare professionals to evidence-based antiemetic guidelines and improved adherence by patients to antiemetic regimens. (emjreviews.com)
  • In addition, as patient-specific risk factors are better defined, these can be incorporated into individualised regimens to obtain optimal antiemetic prophylaxis for that individual. (emjreviews.com)
  • However, few high-quality reports are available on the evaluation of olanzapine's efficacy and safety at a low dose of 5 mg among patients treated with carboplatin regimens. (elsevierpure.com)
  • Therefore, in this study, we investigated the efficacy and safety of 5 mg olanzapine for managing nausea and vomiting in cancer patients receiving carboplatin regimens and identified patient-related risk factors for carboplatin regimen-induced nausea and vomiting treated with 5 mg olanzapine. (elsevierpure.com)
  • Novel approaches, such as selective estrogen receptor modulators, tissue selective estrogen complex, estetrol, and neurokinin B inhibitors show promise as treatments for menopause symptoms, as they are thought to pose less breast cancer risk, according to the study. (pharmacytimes.com)
  • Encodes the G protein-coupled receptor tachykinin receptor 3 (TACR3) also called neurokinin B (NKB) receptor. (chuv.ch)
  • Analysis of brain tissue from post-menopausal women has previously revealed elevated levels of NKB in their brains, while giving the chemical to younger patients has been found to induce flushing. (telegraph.co.uk)
  • Identifying risk factors for CINV in patients with CRC is important to providing them with appropriate care. (biomedcentral.com)
  • EMEND capsules in adults and pediatric patients 12 years of age and older: is 125 mg on Day 1 and 80 mg on Days 2 and 3. (nih.gov)
  • EMEND for oral suspension in pediatric patients 6 months to less than 12 years of age or pediatric and adult patients unable to swallow capsules: see dosing recommendations in Table 3 in the Full Prescribing Information. (nih.gov)
  • Patients should also maintain target levels of vitamin D and calcium, as well as engage in physical activity to relieve menopause symptoms without drugs, according to the study. (pharmacytimes.com)
  • One of the things that we came across almost by serendipity was neurokinin B in menopause. (neuroendo.org.uk)
  • These findings are important because moderately emetogenic chemotherapies are used in diverse patient populations, and adequate control of nausea and vomiting remains a significant challenge with these agents. (hospitalhealthcare.com)
  • Additionally, the authors recommend that VMS symptoms should be treated with cognitive behavioral therapy, hypnosis, and acupuncture among these patients. (pharmacytimes.com)
  • Patients who received both drugs had superior control of symptoms compared with patients who received one or the other. (brad.ac.uk)
  • Patients are seriously ill, with symptoms of mediastinitis. (msdmanuals.com)
  • We were particularly interested in assessing safety and itch intensity as reported by the patient or the parent. (cochrane.org)
  • Participants who received serlopitant at doses of 0.25 mg, 5 mg, and 1 mg may be more likely to experience reduced itch intensity, as reported by the patient, when compared with participants given placebo (low-certainty evidence). (cochrane.org)
  • Certainty of the evidence was low for patient-reported itch intensity because 45% of participants had an identifiable skin disease and 55% had itch of poorly defined cause. (cochrane.org)
  • Uncontrolled nausea and vomiting can limit the effectiveness of cancer therapy and reduce patient quality of life. (hospitalhealthcare.com)
  • Systemic toxicities of anthracyclines (myelosuppression, mucositis, nausea/vomiting) are seen in patients with non-intact bladders. (worthingtoncaron.com)
  • The primary endpoint was the proportion of patients with HSR, and the secondary endpoints were the proportion of patients with "no vomiting", "no significant nausea", and complete response, respectively. (elsevierpure.com)
  • However, the authors caution there have not been enough studies to confirm the safety of the treatments among patients with a history of breast cancer. (pharmacytimes.com)
  • 2014). TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine . (neuromics.com)
  • The diagnosis of migraine is based on patient history. (medscape.com)
  • Neuroimaging is not necessary in patients with a history of recurrent migraine headaches and a normal neurologic examination. (medscape.com)
  • Don't perform neuroimaging studies in patients with stable headaches that meet criteria for migraine. (medscape.com)
  • Over a 20-year period she unpicked the exact mechanism that she thought was causing the menopausal flushing in a rat, which was neurokinin B (NKB). (neuroendo.org.uk)
  • Mutations of the KAL1 gene, which encodes a putative neural cell adhesion molecule (anosmin), have been described in several patients with X-linked Kallmann syndrome. (medscape.com)
  • Loss-of-function mutations of the gene encoding fibroblast growth factor receptor 1 (FGFR1) have been described in patients with autosomal dominant Kallmann syndrome. (medscape.com)
  • Mutations of the gene encoding fibroblast growth factor 8 have been found in a small minority of patients with autosomal dominant Kallmann syndrome. (medscape.com)
  • In one patient, isolated bioinactive luteinizing hormone (LH) was present as a result of a homozygous mutation in the LH beta subunit gene, which prevented binding of LH to its receptor. (medscape.com)
  • In adult patients, factors associated with poor survival include persistence of plasma neurokinin A (NKA), urinary 50-hydroxyindolacetic acid output, age, and 5 or more liver metastases. (medscape.com)
  • In the present study, 13 adult patients who had received mechanical ventilation for ≥24 hours were prospectively recruited. (accjournal.org)
  • Neurokinin A was shown to be a potent chemo attractor for T-cells increasing the migration into infected tissues. (wikipedia.org)
  • Learn how to provide encouragement and social activity prescriptions during visits, and gain essential knowledge to preserve cognitive function, ultimately improving patient care and quality of life. (tunein.com)
  • These drugs are making it possible for patients with the condition to have a better quality of life for several years. (leafydoc.com)
  • Refractory and unexplained chronic cough significantly impair patients' quality of life, impacting their physical and psychological health, and everyday life. (ersjournals.com)
  • It might seem like a stretch, even in the midst of a pandemic, but New York's largest health care provider, Manhasset-based Northwell Health, appears sufficiently convinced by the biological rationale to get behind a phase III trial of tradipitant, a neurokinin-1 (NK1) receptor blocker, which Washington-based Vanda Pharmaceuticals Inc. is already testing in phase III trials in atopic dermatitis, gastroparesis and motion sickness. (bioworld.com)
  • and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. (yahoo.com)
  • Early clinical studies (phase I) have indicated a role for ddIno in the treatment of patients wit. (shengsci.com)
  • That treatment is now in phase 3 trials and a treatment should be available to patients worldwide in the next couple of years. (neuroendo.org.uk)
  • He said the findings, from the proof of concept study would now need to be tested over the long term in a larger group of patients. (telegraph.co.uk)
  • Utility of polygenic scores for differentiating diabetes diagnosis among patients with atypical phenotypes of diabetes. (medscape.com)
  • In this study, 1275 IRGs were curated and their expression changes investigated in 2467 postmortem brains of controls and patients with six major brain disorders, including schizophrenia (SCZ), bipolar disorder (BD), autism spectrum disorder (ASD), major depressive disorder (MDD), Alzheimer's disease (AD), and Parkinson's disease (PD). (nature.com)
  • The included study did not report the effects of this drug on depression and patient satisfaction. (cochrane.org)
  • [ 126 ] In one retroactive study, survival of patients with sigmoid colon was only 33% while 99% of those with appendiceal tumor had survived. (medscape.com)
  • Dr Bayraktutan is the Chief investigator of the Dunhill Medical Trust EPC study investigating the specific effect of ageing on the circulatory level and functional aspects of endothelial progenitor cells as well as the diagnostic and prognostic value of endothelial progenitor cells in elderly patients with lacunar or cortical stroke. (nottingham.ac.uk)
  • A new study finds that adipocyte SLC7A10 impairments may impact lipid accumulation during insulin resistance in patients with obesity. (medscape.com)
  • Metabolites as Risk Factors for Diabetic Retinopathy in Patients with Type 2 Diabetes: a 12-year Follow-up Study. (medscape.com)
  • Before the main trial in which respiratory polygraphy will be used to evaluate postextubation sleep apnea in critically ill patients, we performed a prospective pilot study to ensure that any issues with the conduct of the trial would be identified. (accjournal.org)
  • In a recent study in which postextubation sleep apnea was investigated in Caucasian patients admitted to the surgical ICU, 70% of the patients had sleep apnea [ 8 ]. (accjournal.org)
  • The purpose of this study was to explore the effect of stenting versus aggressive medical management on preventing recurrent stroke in patients with sICAS. (bvsalud.org)
  • Using patient-reported outcomes, this cohort study assessed the perceived impact of chronic cough on QoL and everyday life in patients from outpatient hospital clinics with refractory chronic cough (RCC) or unexplained chronic cough (UCC). (ersjournals.com)
  • Patient-reported outcomes in multiple sclerosis: a prospective registry cohort study. (qmul.ac.uk)
  • TAC3/TACR3 is critical during neonatal period and puberty, but recovery cases in adulthood have been described in some patients carrying TACR3 mutations (Gianetti, Tusset et al. (chuv.ch)
  • Of 827 evaluable, 272 of 414 patients (65.7%) in Arm P had a CR at the 0-120 h period when compared with 244 of 413 (59.1%) in Arm G ( P = 0.0539). (medscape.com)
  • However, these results were based on analyses of patients with various cancers, including many patients with breast cancer. (biomedcentral.com)
  • The authors concluded that each patient should receive individualized treatment that meets their needs, while not putting them at risk for recurrent disease. (pharmacytimes.com)
  • The number of patients with drug-related adverse events, serious adverse events (including deaths) and adverse events resulting in discontinuation were similar in the two treatment groups. (hospitalhealthcare.com)
  • The researchers found that the compound MLE4901 significantly reduced the average total number of flushes during the four-week treatment period, as well as their severity, compared to when the patients received the placebo for four weeks. (telegraph.co.uk)
  • Two of the seven patients who received corticosteroids and one of the other three patients who did not receive this medication had an REI ≥5/hr. (accjournal.org)
  • In a future trial to evaluate postextubation sleep apnea in critically ill patients, pre-stratification based on the use of corticosteroids and high-flow oxygen therapy should be considered. (accjournal.org)
  • Characterization of dystrophic epidermolysis bullosa patients for collagen VII therapy. (stanford.edu)
  • Glucagon-like peptide 1 Analogues as Adjunctive Therapy for Patients with Type 1 Diabetes: an Updated Systematic Review and Meta-analysis. (medscape.com)
  • None of the patients receiving high-flow oxygen therapy had an REI ≥5/hr. (accjournal.org)
  • Consequently, approximately ¥170 million (US $1.6 million) was unnecessarily spent on prophylactic antiemetic drugs for these patients. (urotoday.com)
  • The judicious use of these drugs could spare the burden of extra costs and the potential risk for adverse effects for patients. (urotoday.com)
  • Medical cannabis, therefore, as opposed to other drugs, appears to be an excellent alternative to treat Parkinson's patients and manage pain due to nerve damage. (leafydoc.com)
  • Evaluation of Endothelial Progenitor Cell Characteristics as Clinical Biomarkers for Elderly Patients with Ischaemic Stroke Stem Cell Reviews and Reports. (nottingham.ac.uk)
  • Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients with Recessive Dystrophic Epidermolysis Bullosa. (stanford.edu)
  • That is the most exciting thing - using the science to understand the physiology and, if you can do that, you can generate new therapies for patients. (neuroendo.org.uk)
  • Development of targeted therapies with different sites of action may foster a precision medicine approach to treat this heterogeneous, underserved patient population. (qub.ac.uk)
  • Public drug and device companies may want to think twice before eagerly jumping on the COVID-19 bandwagon with announcements overselling their efforts to develop or repurpose products to treat patients infected with the coronavirus. (bioworld.com)
  • CBD has anti-inflammatory qualities, can reduce pain, and even fully treat pain in some patients. (leafydoc.com)
  • [ 125 ] In patients with carcinoid tumors located in the appendix, age, primary tumor size, histologic features, lymph node involvement, and distant metastasis are significant factors in predicting survival. (medscape.com)
  • Overall, localized carcinoid tumor which is completely resected has an excellent prognosis, the outcome for patients with metastasis, however, remains poor. (medscape.com)
  • Two of the three patients with an REI ≥5/hr underwent in-laboratory polysomnography. (accjournal.org)
  • Additionally both SP neurokinin A is found in the neurosensory system and modulates a wide range of inflammatory and tissue repairing processes [1]. (wikipedia.org)